^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

RAF265

i
Other names: RAF265, CHIR-265
Company:
Novartis
Drug class:
BRAF inhibitor, VEGFR-2 inhibitor
4years
Clinical • Phase classification
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
RAF265
almost7years
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations (clinicaltrials.gov)
P1, N=69, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
Clinical • Trial completion
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
|
Mektovi (binimetinib) • RAF265